Clinical Trials Browser

Has results × Neoplasms, Plasma Cell × Fibroblast Growth Factor 7 × Clear all

NCT01237951 2020-05-05

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Phase 2 Completed

75 enrolled 11 charts

Neoplasms, Plasma Cell